MitoChem Therapeutics is led by a small, highly focused team built to efficiently advance our lead program, MC16, through IND-enabling development. Our team combines deep expertise in neurodegeneration, mitochondrial biology, and translational drug development with disciplined operational execution. As we progress toward clinical readiness, MitoChem is preparing to expand into a world-class organization with seasoned leadership across clinical, regulatory, operational and commercial functions.